Atlas Trials

A Study to Investigate the Safety, Tolerability, and Efficacy of BxC-I17e Single and Multiple Dose SC Injection in Patients With Moderate to Severe Atopic Dermatitis

Clinical trial NCT06055361 · RECRUITING

Trial details

NCT number
NCT06055361
Sponsor
Brexogen Inc.
Status
RECRUITING
Phase
Phase 1
Study type
INTERVENTIONAL
Atopic Dermatitis
Start date
2023-04-18
Primary completion
2026-03-31
Enrollment
45

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.